Two Federal Records, Two Different Answers
The pharmaceutical industry says it still cannot make enough estrogen patches to meet American demand. The federal government's official shortage list states that the country has no shortage. Both statements are current, and the space between them is where patients are stuck.
Manufacturers reiterated this week that supply remains constrained, according to reporting by The Hill, which noted that the American Society of Health-System Pharmacists lists more than a dozen estradiol patch products from five manufacturers as short on supply, with Sandoz accounting for the largest share. Sandoz told the outlet that the market is "experiencing supply challenges affecting HRT patches," citing a global shortage and a sharp rise in demand. The FDA has still not added estradiol patches to its own drug shortage database.
That is not so much a contradiction as two systems measuring different things. The FDA evaluates whether total supply across all manufacturers meets historical national demand. ASHP builds its bulletins from reports submitted by pharmacists, physicians, nurses, and patients, then verifies them with manufacturers. A product can be on back order at one company while another absorbs the volume, which keeps the national picture whole on paper and leaves a specific patient standing at a specific counter without her prescription.
For households, the designation is not a technicality. Formal FDA recognition of a shortage unlocks certain regulatory flexibilities for compounding and shapes how insurers, pharmacy benefit managers, and health systems triage substitutions. Without it, a patient who cannot fill her patch is largely on her own to call around, ask about a different manufacturer, or return to her prescriber for a different product.
A Demand Curve That Manufacturing Could Not Follow
The imbalance is not the result of a factory failure. It is the result of a prescribing shift that arrived faster than production lines could expand.
Prescriptions for estrogen patches rose 162 percent over two years, CNBC reported, citing HealthVerity data. The same data show patch prescriptions climbing from 594,000 in June 2024 to 1.6 million in May of this year, at which point patches accounted for 44 percent of all estrogen prescriptions. Demand accelerated after the FDA moved in November to remove the boxed warning that had discouraged menopausal hormone therapy for more than two decades.
Viatris has said it is working to expand production over the longer term. Those are company statements about their own lines, not a national assessment, and they are part of why ASHP and the FDA can both be reporting accurately. FDA Commissioner Marty Makary has said the labeling change caused a large increase in demand but not enough to constitute a shortage.
Transdermal patches are not simple products to scale. Adhesive chemistry, drug-in-matrix formulation, and release-rate consistency must be consistent across strengths, and only a small number of manufacturers supply the United States market. CNBC reported that catching up could take at least a year.
The practical texture of this is uneven. Availability differs by strength, manufacturer, wholesaler, and individual pharmacy, sometimes even within the same city, which is why one patient can fill a prescription in a neighborhood where another cannot.
The Cost and Access Problem Underneath the Supply Problem
The patch matters clinically for a specific reason, and that reason is why substitution is not a neutral swap.
Transdermal estradiol bypasses first-pass hepatic metabolism, which is associated with a lower risk of clotting than oral estrogen. Clinicians have told NPR that the shift in how estrogen is delivered is much of why demand moved toward patches in the first place. Patients moved to the patch for safety reasons, but a shortage is pushing some of them back toward the option they moved away from.
There are FDA-approved alternatives that preserve the transdermal route, including gels and sprays, as well as oral options. Which one fits depends on medical history, and that is a prescriber's decision rather than a pharmacy-counter improvisation.
Cost enters here too. The patch has generally been the most widely used form of hormone therapy. Gels and sprays may be listed differently on a formulary, may carry a higher copay, or may require prior authorization, which can add days. Compounded hormone products are sometimes offered as a workaround, but they do not undergo the same FDA approval and standardization process as approved products, and they are frequently not covered by insurance.
Difficulty filling a prescription is not rare. In a survey by a menopause telehealth company, 44 percent of nearly 8,000 women across 49 states reported trouble filling an estrogen patch prescription, and 34 percent of those said it had significantly affected their well-being. That figure comes from a company operating in the menopause care market and should be read as survey data from an interested party, though it is consistent with what pharmacists and clinicians have described publicly.
Practical Steps While This Resolves
The most useful first move is specificity. Rather than asking a pharmacist whether estradiol patches are available, patients can ask about a specific manufacturer and strength, because the answer often varies. Asking the pharmacy to check other strengths of the same product before assuming nothing is available is also worth doing. On PBS NewsHour, Northwestern gynecologist Dr. Lauren Streicher made the same point, noting that different pharmacies use different distributors.
Patients should not cut, split, ration, or combine patches to stretch a supply. Patch designs differ in adhesive, surface area, and release mechanism, and altering any one of these can unpredictably change the delivered dose. Anyone considering a change should raise it with a prescriber rather than improvising.
For people facing a coverage obstacle after switching products, the standard avenues apply: asking the prescriber about prior authorization, filing an appeal, asking whether a different approved formulation is on the formulary, and asking about manufacturer patient assistance programs.
Two things remain unresolved. No manufacturer has published a reliable end date, and the FDA has not indicated whether it intends to revisit the shortage designation. The agency has said supply is keeping pace, a characterization that leaves little margin, and its tracking depends on manufacturer-reported figures rather than on prescriptions that go unfilled.
Key Questions Answered
Is there officially a shortage? It depends on the source. ASHP lists more than a dozen estradiol patch products from five manufacturers as short. The FDA has not added estradiol patches to its shortage database, which uses a national supply-versus-demand test.
Why does the designation matter? Formal FDA recognition affects regulatory flexibility around compounding and influences how insurers and health systems handle substitutions. Without it, patients largely navigate the gap on their own.
Why did demand rise so sharply? Patch prescriptions rose 162 percent over two years, and demand accelerated after the FDA moved in November to remove the longstanding boxed warning on hormone therapy.
Are all patches unavailable? No. This is an uneven shortage. Stock varies by manufacturer, strength, wholesaler, and individual pharmacy, sometimes within the same city.
Can someone cut or stretch a patch to make it last? No. Patch designs differ in their adhesive and release mechanisms, and altering one can unpredictably change the dose. Speak with a prescriber instead.
What alternatives exist? FDA-approved gels, sprays, and oral formulations. Which is appropriate depends on individual medical history and is a prescriber's decision.
How long will this last? No manufacturer has published a reliable end date. Reports suggest supply could take at least a year to catch up.
